Cargando…

Cannabidiol Administered During Peri-Adolescence Prevents Behavioral Abnormalities in an Animal Model of Schizophrenia

Schizophrenia is considered a debilitating neurodevelopmental psychiatric disorder and its pharmacotherapy remains problematic without recent major advances. The development of interventions able to prevent the emergence of schizophrenia would therefore represent an enormous progress. Here, we inves...

Descripción completa

Detalles Bibliográficos
Autores principales:	Peres, Fernanda F., Diana, Mariana C., Levin, Raquel, Suiama, Mayra A., Almeida, Valéria, Vendramini, Ana M., Santos, Camila M., Zuardi, Antônio W., Hallak, Jaime E. C., Crippa, José A., Abílio, Vanessa C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2018
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6113576/ https://www.ncbi.nlm.nih.gov/pubmed/30186164 http://dx.doi.org/10.3389/fphar.2018.00901

Ejemplares similares

Cannabidiol, among Other Cannabinoid Drugs, Modulates Prepulse Inhibition of Startle in the SHR Animal Model: Implications for Schizophrenia Pharmacotherapy
por: Peres, Fernanda F., et al.
Publicado: (2016)

Cannabidiol Prevents Motor and Cognitive Impairments Induced by Reserpine in Rats
por: Peres, Fernanda F., et al.
Publicado: (2016)

Is Cannabidiol During Neurodevelopment a Promising Therapy for Schizophrenia and Autism Spectrum Disorders?
por: Loss, Cássio Morais, et al.
Publicado: (2021)

Effects of cannabinoid drugs on the deficit of prepulse inhibition of startle in an animal model of schizophrenia: the SHR strain
por: Levin, Raquel, et al.
Publicado: (2014)

Cannabidiol as a Promising Strategy to Treat and Prevent Movement Disorders?
por: Peres, Fernanda F., et al.
Publicado: (2018)

Δ9-THC Intoxication by Cannabidiol-Enriched Cannabis Extract in Two Children with Refractory Epilepsy: Full Remission after Switching to Purified Cannabidiol
por: Crippa, José A. S., et al.
Publicado: (2016)

Evaluation of Serum Cytokines Levels and the Role of Cannabidiol Treatment in Animal Model of Asthma
por: Vuolo, Francieli, et al.
Publicado: (2015)

Cannabidiol induces autophagy via ERK1/2 activation in neural cells
por: Vrechi, Talita A. M., et al.
Publicado: (2021)

The anxiolytic effect of cannabidiol depends on the nature of the trauma when patients with post-traumatic stress disorder recall their trigger event
por: Bolsoni, Lívia Maria, et al.
Publicado: (2022)

No Acute Effects of Cannabidiol on the Sleep-Wake Cycle of Healthy Subjects: A Randomized, Double-Blind, Placebo-Controlled, Crossover Study
por: Linares, Ila M. P., et al.
Publicado: (2018)

Biological bases for a possible effect of cannabidiol in Parkinson’s disease
por: Ferreira-Junior, Nilson C., et al.
Publicado: (2019)

Inverted U-Shaped Dose-Response Curve of the Anxiolytic Effect of Cannabidiol during Public Speaking in Real Life
por: Zuardi, Antonio W., et al.
Publicado: (2017)

Cannabidiol for the treatment of crack-cocaine craving: an exploratory double-blind study
por: de Meneses-Gaya, Carolina, et al.
Publicado: (2020)

Cannabidiol Displays Proteomic Similarities to Antipsychotics in Cuprizone-Exposed Human Oligodendrocytic Cell Line MO3.13
por: Falvella, Ana Caroline Brambilla, et al.
Publicado: (2021)

F198. EFFECTS OF CANNABINOIDS ON A HUMAN OLIGODENDROCYTE CULTURE: IMPLICATIONS FOR SCHIZOPHRENIA
por: Almeida, Valéria, et al.
Publicado: (2018)

Corrigendum: Cannabidiol Displays Proteomic Similarities to Antipsychotics in Cuprizone-Exposed Human Oligodendrocytic Cell Line MO3.13
por: Falvella, Ana Caroline Brambilla, et al.
Publicado: (2021)

Evaluation of the role of the cannabidiol system in an animal model of ischemia/reperfusion kidney injury
por: Soares, Rodrigo Zon, et al.
Publicado: (2015)

Antiapoptotic effects of cannabidiol in an experimental model of cognitive decline induced by brain iron overload
por: da Silva, Vanessa Kappel, et al.
Publicado: (2018)

Translational Investigation of the Therapeutic Potential of Cannabidiol (CBD): Toward a New Age
por: Crippa, José A., et al.
Publicado: (2018)

Adverse Effects of Oral Cannabidiol: An Updated Systematic Review of Randomized Controlled Trials (2020–2022)
por: Souza, José Diogo R., et al.
Publicado: (2022)

Systemic Chronic Treatment with Cannabidiol in Carioca High- and Low-Conditioned Freezing Rats in the Neuropathic Pain Model: Evaluation of Pain Sensitivity
por: Macêdo-Souza, Carolina, et al.
Publicado: (2023)

Marijuana, feijoada and the debate on drug legalization
por: Crippa, José A. S., et al.
Publicado: (2013)

17.4 POSSIBLE MECHANISMS INVOLVED IN THE ANTIPSYCHOTIC EFFECTS OF CANNABIDIOL (CBD)
por: Crippa, Jose Alexandre, et al.
Publicado: (2018)

Effect of two oral formulations of cannabidiol on responses to emotional stimuli in healthy human volunteers: pharmaceutical vehicle matters
por: Crippa, José A., et al.
Publicado: (2021)

A Conversion of Oral Cannabidiol to Delta9-Tetrahydrocannabinol Seems Not to Occur in Humans
por: Nahler, Gerhard, et al.
Publicado: (2017)

Fluorinated Cannabidiol Derivatives: Enhancement of Activity in Mice Models Predictive of Anxiolytic, Antidepressant and Antipsychotic Effects
por: Breuer, Aviva, et al.
Publicado: (2016)

Protective Effects of Cannabidiol against Seizures and Neuronal Death in a Rat Model of Mesial Temporal Lobe Epilepsy
por: Do Val-da Silva, Raquel A., et al.
Publicado: (2017)

Correction: Fluorinated Cannabidiol Derivatives: Enhancement of Activity in Mice Models Predictive of Anxiolytic, Antidepressant and Antipsychotic Effects
por: Breuer, Aviva, et al.
Publicado: (2016)

Case Report: Cannabidiol-Induced Skin Rash: A Case Series and Key Recommendations
por: Souza, José Diogo S., et al.
Publicado: (2022)

Dr. Raphael Mechoulam, cannabis and cannabinoids research pioneer (November 5, 1930–March 9, 2023) and his legacy for Brazilian pharmacology
por: Crippa, José Alexandre S., et al.
Publicado: (2023)

Maternal administration of cannabidiol promotes an anti-inflammatory effect on the intestinal wall in a gastroschisis rat model
por: Callejas, G.H., et al.
Publicado: (2018)

Convergent evidences from human and animal studies implicate angiotensin I-converting enzyme activity in cognitive performance in schizophrenia
por: Gadelha, A, et al.
Publicado: (2015)

Cannabidiol Is a Potential Therapeutic for the Affective-Motivational Dimension of Incision Pain in Rats
por: Genaro, Karina, et al.
Publicado: (2017)

Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test
por: Linares, Ila M., et al.
Publicado: (2018)

Sex-dependent differences in the anxiolytic-like effect of cannabidiol in the elevated plus-maze
por: Fabris, Débora, et al.
Publicado: (2022)

Potential cannabidiol (CBD) repurposing as antibacterial and promising therapy of CBD plus polymyxin B (PB) against PB-resistant gram-negative bacilli
por: Abichabki, Nathália, et al.
Publicado: (2022)

A False Case of Clozapine-Resistant Schizophrenia
por: Maia-de-Oliveira, J. P., et al.
Publicado: (2010)

Pharmacological interventions in the treatment of the acute effects of cannabis: a systematic review of literature
por: Crippa, José AS, et al.
Publicado: (2012)

Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia
por: Leweke, F M, et al.
Publicado: (2012)

Pharmacokinetic modelling of orally administered cannabidiol and implications for medication control in horses
por: Eichler, Fabienne, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_9nmundjf07r5to8a1sie4ibvm1